DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT05482789

RecruitingPhase 4

Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes

Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes

Asset

Exenatide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

1

Enrollment

13

estimated

Study population

Gestational diabetes

Key I/E criterion

•Female

Primary endpoint

•AUC of glucose

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05482789
Org study IDSTUDY22070080

Timeline

Milestones

Study first posted2022-08-01actual
Study start2023-04-12actual
Primary completion2025-12-31actual
Last update posted2026-04-20actual
Study completion2026-12-31estimated

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Gestational diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age50 Years
SexFemale
Healthy volunteersNot accepted

Inclusion criteria

•Pregnant women (singleton)
•Gestational diabetes not requiring medical therapy
•Between 18 and 50 years of age
•Able to give written informed consent

Exclusion criteria

•Women in the first trimester of pregnancy
•Hematocrit less than 30%
•Current or past treatment with any hypoglycemic agent
•Women with gastrointestinal disease or symptoms consistent with nausea, vomiting, abdominal pain or reflux requiring medical treatment.
•Women with high triglyceride levels, history of gallbladder or pancreatic disease.
•Clinical diagnosis or history of any renal insufficiency (or decreased creatinine clearance)

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
1
Safety / tolerability / PK
1

Glycemic / diabetes

1 endpoint
Primary/protocol endpoint

Area Under the Plasma Concentration Versus Time Curve (AUC) of glucose

Time frame:Baseline and 1 week later

descriptive

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Area Under the Plasma Concentration Versus Time Curve (AUC) of exenatide

Time frame:1 week after study enrollment

AUC₀–∞

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.